Does Flonase Help with COVID-19?
No, intranasal fluticasone (Flonase) is not recommended for treating or preventing COVID-19 based on current evidence, and the highest quality randomized trial showed no benefit for symptom resolution or preventing hospitalization.
Evidence from Clinical Trials
The most definitive evidence comes from the ACTIV-6 trial, a large, double-blind, randomized, placebo-controlled study that specifically tested inhaled fluticasone furoate (a closely related formulation to Flonase) in 1,407 outpatients with COVID-19 1. This trial found:
- No reduction in time to recovery (hazard ratio 1.01; 95% CI 0.91-1.12)
- No prevention of hospitalization or death (3.7% in fluticasone group vs 2.1% in placebo group)
- The fluticasone group actually had numerically more urgent care/emergency department visits or hospitalizations, though not statistically significant
This high-quality 2023 study directly contradicts any benefit for COVID-19 treatment and should guide clinical decision-making.
What About Other Evidence?
While some smaller studies suggested potential mechanisms of benefit 2, 3, 4, these were either:
- In vitro laboratory studies showing barrier protection effects 2
- Small observational studies with methodological limitations 3
- Review articles discussing theoretical potential 4
None of these override the negative findings from the large randomized controlled trial.
Observational Data on Safety
Retrospective cohort studies provide some reassurance that intranasal corticosteroid use doesn't worsen COVID-19 outcomes 5. Among patients with asthma and COPD, prior INCS exposure showed no adverse effect on COVID-19 mortality, though it also showed no clear protective benefit.
Current Guideline Position
International guidelines from 2020 6 emphasized that there was no evidence for specific anti-COVID-19 treatments and recommended investigational therapies only be used in approved clinical trials. The WHO living guideline 7 does not include intranasal corticosteroids in its recommendations for COVID-19 treatment.
What Flonase IS Approved For
The FDA-approved indications for Flonase are limited to allergic rhinitis symptoms: nasal congestion, itchy/watery eyes, runny nose, and sneezing caused by allergens like pollen, mold, dust, or pet dander 8. It has no approved indication for viral respiratory infections.
Clinical Bottom Line
Do not prescribe or recommend intranasal fluticasone for COVID-19 treatment or prevention. If patients with COVID-19 have concurrent allergic rhinitis requiring treatment, intranasal corticosteroids appear safe to continue but should not be expected to impact COVID-19 outcomes. Focus instead on evidence-based COVID-19 therapies appropriate to disease severity and risk stratification.
Common Pitfall to Avoid
Do not extrapolate the proven benefits of systemic corticosteroids (like dexamethasone) in hospitalized COVID-19 patients requiring oxygen to intranasal corticosteroids in outpatients—these are entirely different interventions with different mechanisms, delivery routes, and evidence bases 9, 10.